Trial intelligence / Profile preview

Phase II Study of BMS-354825 (dasatinib) in Lymphoid Blast Phase CML and Ph+ ALL Resistant to Imatinib

2004-002517-36Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Nov 2004

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1